Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Pancreatic Cancer Approved as Add'l Indication for Tarceva: Chugai
July 18, 2011
- DPC Subcommittee to Look at Fixed-sum Reimbursement per Hospitalization for High-priced Drugs
July 18, 2011
- Further Consolidation of Dispensing Pharmacies Expected: Mr Ubunuki of Yano Research
July 18, 2011
- GSK Obtains Marketing Approval for Rotarix
July 18, 2011
- Taisei Kako Co-develops New Prefilled Syringe with Suzuken
July 18, 2011
- Kyowa Kirin to Enforce Safe Driver Education for New MRs
July 18, 2011
- 3 Products Including 4-Valent HPV Vaccine Gardasil Approved: MSD
July 18, 2011
- Nippon Kayaku Takes over Manufacturing Approval for Gelpart from Astellas
July 18, 2011
- Korosho to Announce Stance on Copayments for OTC-like Drugs by Year-end
July 18, 2011
- Takeda Obtains Approval for Liovel Combination Tab
July 18, 2011
- Korosho Panel Fails to Form Consensus on HbA1c Data Reporting
July 18, 2011
- Onbrez Approved for COPD: Novartis
July 18, 2011
- Hepatitis B Settlements May Require General Tax Increase: Health Minister Hosokawa
July 18, 2011
- Antiepileptic Agent Rufinamide Approved in Canada: Eisai
July 18, 2011
- Over 70% of Women Aware of HPV Vaccine: Survey
July 18, 2011
- FDA Committee Recommends Withdrawal of Breast Cancer Indication from Avastin
July 18, 2011
- Bristol-Myers to Create Friendlier Work Environment for Women
July 18, 2011
- Council on Unapproved Drugs to Revise Assessment Criteria
July 18, 2011
- STATISTICS
July 18, 2011
- Sales of Ethical Drugs Up 7.5% in May: Crecon & Research Consulting
July 18, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…